来自II期临床试验的分析,Alvelestat, NE(中性粒细胞弹性酶)抑制剂治疗AATD-LD:生物标志物反应(Desmosine和Aa-val360)与临床结果(SGRQ)的相关性

J. Parkin, S. Rabbie, I. Black, J. Inshaw
{"title":"来自II期临床试验的分析,Alvelestat, NE(中性粒细胞弹性酶)抑制剂治疗AATD-LD:生物标志物反应(Desmosine和Aa-val360)与临床结果(SGRQ)的相关性","authors":"J. Parkin, S. Rabbie, I. Black, J. Inshaw","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2844","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":205419,"journal":{"name":"B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1","volume":"38 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Analysis From Phase II Clinical Trial, Alvelestat, NE (Neutrophil Elastase) Inhibitor in AATD-LD: Correlation Between Biomarker Response (Desmosine and Aa-val360) and Clinical Outcome (SGRQ)\",\"authors\":\"J. Parkin, S. Rabbie, I. Black, J. Inshaw\",\"doi\":\"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2844\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":205419,\"journal\":{\"name\":\"B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1\",\"volume\":\"38 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2844\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2844","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Analysis From Phase II Clinical Trial, Alvelestat, NE (Neutrophil Elastase) Inhibitor in AATD-LD: Correlation Between Biomarker Response (Desmosine and Aa-val360) and Clinical Outcome (SGRQ)
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信